🇺🇸 FDA
Patent

US 10029017

Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug

granted A61KA61K38/06A61K47/60

Quick answer

US patent 10029017 (Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug) held by The Regents of the University of California expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K38/06, A61K47/60, A61K47/64, A61K47/645